Newly Created Hybrid Nanomaterial for Treatment of Lung Carcinoma

Abstract

Deficient passage of therapeutic cargo into tumor bed is a bottleneck in cancer nanomedicine. Interest has been manifested in use of chitosan-based nanoparticles with utilizing metal oxide hybrid nanocomposite in nanomedicine. We synthesis, characterize, and investigate a hybrid nanomaterial (CHNM) anti-cancer activity. A developed CHNM of magnesium oxide nanoparticles coupled with cisplatin and coated with chitosan biopolymer were characterized by FTIR, X-ray diffraction, TEM and SEM. Anti-cancer effects were evaluated in A549 cell line. CHNM nanoparticles showed a diameter of ∼240 nm with a negatively charged surface (-25.4 ± 3.75 mV) and mean particle size of 24.2 ± 7.89 nm. CHNM showed a high encapsulation efficiency (78%), drug loading efficiency (80%) and maximum cisplatin release (2- 6 h). CHNM showed improved anti-cancer activity on A549 cells (IC50=50.8 μg/ml). In conclusion, magnesium oxide nanoparticles coupled with cisplatin and coated with chitosan biopolymer could be used as promising lung cancer treatment system.